Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free BHST Stock Alerts

BioHarvest Sciences (BHST) Competitors

BioHarvest Sciences logo
$4.21 +0.07 (+1.69%)
Closing price 04:00 PM Eastern
Extended Trading
$4.26 +0.04 (+1.07%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BHST vs. CABA, BCYC, DMAC, SOPH, and GLSI

Should you be buying BioHarvest Sciences stock or one of its competitors? The main competitors of BioHarvest Sciences include Cabaletta Bio (CABA), Bicycle Therapeutics (BCYC), DiaMedica Therapeutics (DMAC), SOPHiA GENETICS (SOPH), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry.

How does BioHarvest Sciences compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

In the previous week, Cabaletta Bio had 4 more articles in the media than BioHarvest Sciences. MarketBeat recorded 7 mentions for Cabaletta Bio and 3 mentions for BioHarvest Sciences. Cabaletta Bio's average media sentiment score of 0.47 beat BioHarvest Sciences' score of 0.20 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cabaletta Bio
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioHarvest Sciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cabaletta Bio has a beta of 3.18, indicating that its stock price is 218% more volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.

Cabaletta Bio has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.27%. Cabaletta Bio's return on equity of -121.73% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cabaletta BioN/A -121.73% -90.19%
BioHarvest Sciences -32.27%-136.42%-27.92%

Cabaletta Bio currently has a consensus price target of $17.00, suggesting a potential upside of 309.64%. BioHarvest Sciences has a consensus price target of $10.00, suggesting a potential upside of 137.53%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Cabaletta Bio is more favorable than BioHarvest Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cabaletta Bio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
BioHarvest Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

BioHarvest Sciences has higher revenue and earnings than Cabaletta Bio. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabaletta BioN/AN/A-$167.86M-$2.28N/A
BioHarvest Sciences$34.51M2.39-$11.14M-$0.61N/A

Summary

Cabaletta Bio beats BioHarvest Sciences on 9 of the 13 factors compared between the two stocks.

How does BioHarvest Sciences compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Bicycle Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 185.71%. BioHarvest Sciences has a consensus target price of $10.00, suggesting a potential upside of 137.53%. Given Bicycle Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Bicycle Therapeutics is more favorable than BioHarvest Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicycle Therapeutics
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44
BioHarvest Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Bicycle Therapeutics had 3 more articles in the media than BioHarvest Sciences. MarketBeat recorded 6 mentions for Bicycle Therapeutics and 3 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 0.20 beat Bicycle Therapeutics' score of -0.27 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bicycle Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
BioHarvest Sciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Bicycle Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.

BioHarvest Sciences has a net margin of -32.27% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Bicycle Therapeutics-344.95% -35.74% -29.54%
BioHarvest Sciences -32.27%-136.42%-27.92%

86.2% of Bicycle Therapeutics shares are held by institutional investors. 22.9% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BioHarvest Sciences has lower revenue, but higher earnings than Bicycle Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bicycle Therapeutics$63.50M5.38-$218.96M-$3.15N/A
BioHarvest Sciences$34.51M2.39-$11.14M-$0.61N/A

Summary

Bicycle Therapeutics beats BioHarvest Sciences on 11 of the 16 factors compared between the two stocks.

How does BioHarvest Sciences compare to DiaMedica Therapeutics?

BioHarvest Sciences (NASDAQ:BHST) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

BioHarvest Sciences has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.

DiaMedica Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.27%. DiaMedica Therapeutics' return on equity of -77.72% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
BioHarvest Sciences-32.27% -136.42% -27.92%
DiaMedica Therapeutics N/A -77.72%-69.54%

In the previous week, BioHarvest Sciences had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for BioHarvest Sciences and 2 mentions for DiaMedica Therapeutics. BioHarvest Sciences' average media sentiment score of 0.20 beat DiaMedica Therapeutics' score of 0.00 indicating that BioHarvest Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioHarvest Sciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DiaMedica Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

BioHarvest Sciences has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioHarvest Sciences$34.51M2.39-$11.14M-$0.61N/A
DiaMedica TherapeuticsN/AN/A-$32.77M-$0.70N/A

10.1% of DiaMedica Therapeutics shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioHarvest Sciences presently has a consensus target price of $10.00, suggesting a potential upside of 137.53%. DiaMedica Therapeutics has a consensus target price of $12.33, suggesting a potential upside of 97.65%. Given BioHarvest Sciences' higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than DiaMedica Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioHarvest Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
DiaMedica Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

BioHarvest Sciences beats DiaMedica Therapeutics on 8 of the 15 factors compared between the two stocks.

How does BioHarvest Sciences compare to SOPHiA GENETICS?

SOPHiA GENETICS (NASDAQ:SOPH) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

SOPHiA GENETICS currently has a consensus target price of $7.50, indicating a potential upside of 47.93%. BioHarvest Sciences has a consensus target price of $10.00, indicating a potential upside of 137.53%. Given BioHarvest Sciences' higher probable upside, analysts plainly believe BioHarvest Sciences is more favorable than SOPHiA GENETICS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
BioHarvest Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

SOPHiA GENETICS has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.

BioHarvest Sciences has lower revenue, but higher earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M4.49-$79M-$0.51N/A
BioHarvest Sciences$34.51M2.39-$11.14M-$0.61N/A

BioHarvest Sciences has a net margin of -32.27% compared to SOPHiA GENETICS's net margin of -44.22%. SOPHiA GENETICS's return on equity of -50.60% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-44.22% -50.60% -21.00%
BioHarvest Sciences -32.27%-136.42%-27.92%

31.6% of SOPHiA GENETICS shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, SOPHiA GENETICS had 7 more articles in the media than BioHarvest Sciences. MarketBeat recorded 10 mentions for SOPHiA GENETICS and 3 mentions for BioHarvest Sciences. SOPHiA GENETICS's average media sentiment score of 0.45 beat BioHarvest Sciences' score of 0.20 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SOPHiA GENETICS
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
BioHarvest Sciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

SOPHiA GENETICS beats BioHarvest Sciences on 12 of the 16 factors compared between the two stocks.

How does BioHarvest Sciences compare to Greenwich LifeSciences?

BioHarvest Sciences (NASDAQ:BHST) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, BioHarvest Sciences had 2 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 3 mentions for BioHarvest Sciences and 1 mentions for Greenwich LifeSciences. BioHarvest Sciences' average media sentiment score of 0.20 beat Greenwich LifeSciences' score of 0.00 indicating that BioHarvest Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioHarvest Sciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Greenwich LifeSciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Greenwich LifeSciences has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.27%. BioHarvest Sciences' return on equity of -136.42% beat Greenwich LifeSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
BioHarvest Sciences-32.27% -136.42% -27.92%
Greenwich LifeSciences N/A -1,042.84%-565.43%

BioHarvest Sciences has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.

BioHarvest Sciences currently has a consensus target price of $10.00, indicating a potential upside of 137.53%. Greenwich LifeSciences has a consensus target price of $47.50, indicating a potential upside of 113.00%. Given BioHarvest Sciences' higher probable upside, research analysts clearly believe BioHarvest Sciences is more favorable than Greenwich LifeSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioHarvest Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Greenwich LifeSciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

4.2% of Greenwich LifeSciences shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioHarvest Sciences has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioHarvest Sciences$34.51M2.39-$11.14M-$0.61N/A
Greenwich LifeSciencesN/AN/A-$15.79M-$1.46N/A

Summary

BioHarvest Sciences beats Greenwich LifeSciences on 9 of the 15 factors compared between the two stocks.

Get BioHarvest Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for BHST and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BHST vs. The Competition

Export
MetricBioHarvest SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$82.60M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-6.9038.8529.0428.47
Price / Sales2.39155.51476.6160.92
Price / CashN/A57.8827.6236.52
Price / Book3.247.039.676.67
Net Income-$11.14M$23.62M$3.55B$332.53M
7 Day Performance-2.09%3.68%1.70%2.01%
1 Month Performance-1.64%7.16%5.62%9.19%
1 Year Performance-33.91%67.05%34.41%39.59%

BioHarvest Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BHST
BioHarvest Sciences
2.5601 of 5 stars		$4.21
+1.7%		$10.00
+137.5%		N/A$82.60M$34.51MN/AN/A
CABA
Cabaletta Bio
2.2628 of 5 stars		$2.95
-3.3%		$17.00
+476.3%		N/A$339.54MN/AN/A50
BCYC
Bicycle Therapeutics
3.0378 of 5 stars		$4.84
-0.2%		$14.38
+197.0%		N/A$338.08M$72.86MN/A240
DMAC
DiaMedica Therapeutics
1.1032 of 5 stars		$6.33
+1.8%		$12.33
+94.8%		N/A$335.15MN/AN/A20
SOPH
SOPHiA GENETICS
3.2095 of 5 stars		$4.85
-0.4%		$7.50
+54.6%		N/A$333.53M$77.27MN/A520

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BHST) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel